We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement
News

SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement

SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement
News

SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SOLVO Biotechnology and Hepregen Corporation have announced, at the 13th European Meeting of the International Society for the Study of Xenobiotics ("ISSX"), a co-marketing agreement between the companies. This agreement provides for the European marketing of Hepregen's human, monkey, rat and dog application-directed HepatoPac® and HepatoMuneT kits, which are used for liver metabolite analysis, transport studies and predictive and mechanistic toxicology studies.

These kits contain human or animal hepatocytes (liver cells) in Hepregen's proprietary micro-patterned, co-culture microtiter tissue culture plates. This agreement provides SOLVO with the opportunity to make services available to its customers using these Hepregen products as well as HepatoPac® B-CLEAR® products co-developed by Hepregen and Qualyst Transporter Solutions.

"Hepregen's technology is a welcome addition to our world-recognized portfolio of products and services associated with transporter protein analysis", said Erno Duda, SOLVO's chief executive officer. "As the transporter field matures, we see a growing need for physiologically relevant systems in addition to the established transfected models. Moreover, adding Hepregen's portfolio to ours provides us with an opportunity to broaden our offerings to customers into the important areas of drug metabolism and safety testing. Our partnership with Hepregen enhances SOLVO's ability to grow as a biotechnology enterprise."

Dr. Vincent Zurawski, Hepregen's president and chief executive, stated, "This marketing partnership represents another step in Hepregen's unceasing effort to make our application-directed products and associated services available to customers around the world," adding, "SOLVO's exceptional European sales capability is expected to dramatically augment our already growing European sales effort."

Advertisement